• 1
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 303044.
  • 2
    International Agency for Research on Cancer. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 177240.
  • 3
    Parsonnet J. Helicobacter pylori. Infect Dis Clin North Am 1998; 12: 18597.
  • 4
    Kido M, Tanaka J, Aoki N et al. Helicobacter pylori promotes the production of thymic stromal lymphopoietin by gastric epithelial cells and induces dendritic cell-mediated inflammatory Th2 responses. Infect Immun 2010; 78: 10814.
  • 5
    Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology 2009; 136: 186373.
  • 6
    Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002; 2: 2837.
  • 7
    El-Omar EM, Carrington M, Chow WH et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398402.
  • 8
    Hou L, El-Omar EM, Chen J et al. Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. Carcinogenesis 2007; 28: 11823.
  • 9
    Mahajan R, El-Omar EM, Lissowska J et al. Genetic variants in T helper cell type 1, 2 and 3 pathways and gastric cancer risk in a Polish population. Jpn J Clin Oncol 2008; 38: 62633.
  • 10
    Zheng W, Chow WH, Yang G et al. The Shanghai Women’s Health Study: rationale, study design, and baseline characteristics. Am J Epidemiol 2005; 162: 112331.
  • 11
    World Health Organisation. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Volume 1, 9th Revision. Geneva: WHO; 1977.
  • 12
    Shu XO, Yang G, Jin F et al. Validity and reproducibility of the food frequency questionnaire used in the Shanghai Women’s Health Study. Eur J Clin Nutr 2004; 58: 1723.
  • 13
    Jackson L, Britton J, Lewis SA et al. A population-based epidemiologic study of Helicobacter pylori infection and its association with systemic inflammation. Helicobacter 2009; 14: 10813.
  • 14
    Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975; 2: 5860.
  • 15
    Graham DY, Opekun AR, Osato MS et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut 2004; 53: 123543.
  • 16
    Tebbutt NC, Giraud AS, Inglese M et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002; 8: 108997.
  • 17
    Kim HK, Song KS, Park YS et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003; 39: 18491.
  • 18
    Kabir S, Daar GA. Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett 1995; 95: 20712.
  • 19
    Ilhan N, Ilhan N, Ilhan Y, Akbulut H, Kucuksu M. C-Reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 2004; 10: 111520.
  • 20
    Galizia G, Lieto E, De Vita F et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res 2002; 22: 47382.
  • 21
    De Vita F, Romano C, Orditura M et al. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 2001; 21: 4552.
  • 22
    Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003; 83: 22226.
  • 23
    Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001; 58: 100815.
  • 24
    Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161: 18287.
  • 25
    Nishimura K, Arichi N, Tokugawa S et al. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels. Prostate Cancer Prostatic Dis 2008; 11: 25863.
  • 26
    Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 86067.
  • 27
    Ashizawa T, Okada R, Suzuki Y et al. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2005; 8: 12431.
  • 28
    DeRijk R, Michelson D, Karp B et al. Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha (TNF alpha) production in humans: high sensitivity of TNF alpha and resistance of IL-6. J Clin Endocrinol Metab 1997; 82: 218291.
  • 29
    Marinova S, Nenkov P, Markova R et al. Cellular and humoral systemic and mucosal immune responses stimulated by an oral polybacterial immunomodulator in patients with chronic urinary tract infections. Int J Immunopathol Pharmacol 2005; 18: 45773.
  • 30
    Wong HL, Pfeiffer RM, Fears TR, Vermeulen R, Ji S, Rabkin CS. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomarkers Prev 2008; 17: 345056.
  • 31
    Lee SA, Kallianpur A, Xiang YB et al. Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies. Cancer Epidemiol Biomarkers Prev 2007; 16: 246470.